Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma

L. D. Glenn, James Olen Armitage, J. C. Goldsmith, S. Sorensen, D. Howe, D. D. Weisenberger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtype of non-Hodgkins' lymphomas. Treatment-related complications, however, are considerable, and a common problem encountered is respiratory distress or respiratory insufficiency. Usually these difficulties have been attributed to infectious etiologies or to chemotherapy-induced interstitial fibrosis, most often involving bleomycin. We describe five patients presenting with respiratory problems several weeks after the initiation of chemotherapy. These patients, who represent 3 percent of all patients treated with a single bleomycin-containing regimen for intermediate or high grade non-Hodgkin's lymphoma, were all initially throught to have chemotherapy-induced interstitial fibrosis but were found on subsequent evaluation to have pulmonary emboli. Of the three patients in whom pulmonary emboli were diagnosed antemortem, two had symptoms suggestive of pulmonary emboli and all were successfully treated and remained well and free of lymphoma for over 24 months. Two additional patients were diagnosed at autopsy. We suggest that pulmonary emboli may contribute significantly to the morbidity and mortality of patients undergoing chemotherapy for non-Hodgkin's lymphoma and recommend that patients presenting with respiratory difficulties be evaluated for pulmonary emboli.

Original languageEnglish (US)
Pages (from-to)589-594
Number of pages6
JournalChest
Volume94
Issue number3
DOIs
StatePublished - Jan 1 1988

Fingerprint

Embolism
Non-Hodgkin's Lymphoma
Drug Therapy
Lung
Bleomycin
Fibrosis
Combination Drug Therapy
Respiratory Insufficiency
Autopsy
Lymphoma
Morbidity
Mortality

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Glenn, L. D., Armitage, J. O., Goldsmith, J. C., Sorensen, S., Howe, D., & Weisenberger, D. D. (1988). Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. Chest, 94(3), 589-594. https://doi.org/10.1378/chest.94.3.589

Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. / Glenn, L. D.; Armitage, James Olen; Goldsmith, J. C.; Sorensen, S.; Howe, D.; Weisenberger, D. D.

In: Chest, Vol. 94, No. 3, 01.01.1988, p. 589-594.

Research output: Contribution to journalArticle

Glenn, LD, Armitage, JO, Goldsmith, JC, Sorensen, S, Howe, D & Weisenberger, DD 1988, 'Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma', Chest, vol. 94, no. 3, pp. 589-594. https://doi.org/10.1378/chest.94.3.589
Glenn LD, Armitage JO, Goldsmith JC, Sorensen S, Howe D, Weisenberger DD. Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. Chest. 1988 Jan 1;94(3):589-594. https://doi.org/10.1378/chest.94.3.589
Glenn, L. D. ; Armitage, James Olen ; Goldsmith, J. C. ; Sorensen, S. ; Howe, D. ; Weisenberger, D. D. / Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma. In: Chest. 1988 ; Vol. 94, No. 3. pp. 589-594.
@article{34635311ac7a4e30b2667e31c208b1c6,
title = "Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma",
abstract = "Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtype of non-Hodgkins' lymphomas. Treatment-related complications, however, are considerable, and a common problem encountered is respiratory distress or respiratory insufficiency. Usually these difficulties have been attributed to infectious etiologies or to chemotherapy-induced interstitial fibrosis, most often involving bleomycin. We describe five patients presenting with respiratory problems several weeks after the initiation of chemotherapy. These patients, who represent 3 percent of all patients treated with a single bleomycin-containing regimen for intermediate or high grade non-Hodgkin's lymphoma, were all initially throught to have chemotherapy-induced interstitial fibrosis but were found on subsequent evaluation to have pulmonary emboli. Of the three patients in whom pulmonary emboli were diagnosed antemortem, two had symptoms suggestive of pulmonary emboli and all were successfully treated and remained well and free of lymphoma for over 24 months. Two additional patients were diagnosed at autopsy. We suggest that pulmonary emboli may contribute significantly to the morbidity and mortality of patients undergoing chemotherapy for non-Hodgkin's lymphoma and recommend that patients presenting with respiratory difficulties be evaluated for pulmonary emboli.",
author = "Glenn, {L. D.} and Armitage, {James Olen} and Goldsmith, {J. C.} and S. Sorensen and D. Howe and Weisenberger, {D. D.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1378/chest.94.3.589",
language = "English (US)",
volume = "94",
pages = "589--594",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "3",

}

TY - JOUR

T1 - Pulmonary emboli in patients receiving chemotherapy for non-Hodgkin's lymphoma

AU - Glenn, L. D.

AU - Armitage, James Olen

AU - Goldsmith, J. C.

AU - Sorensen, S.

AU - Howe, D.

AU - Weisenberger, D. D.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtype of non-Hodgkins' lymphomas. Treatment-related complications, however, are considerable, and a common problem encountered is respiratory distress or respiratory insufficiency. Usually these difficulties have been attributed to infectious etiologies or to chemotherapy-induced interstitial fibrosis, most often involving bleomycin. We describe five patients presenting with respiratory problems several weeks after the initiation of chemotherapy. These patients, who represent 3 percent of all patients treated with a single bleomycin-containing regimen for intermediate or high grade non-Hodgkin's lymphoma, were all initially throught to have chemotherapy-induced interstitial fibrosis but were found on subsequent evaluation to have pulmonary emboli. Of the three patients in whom pulmonary emboli were diagnosed antemortem, two had symptoms suggestive of pulmonary emboli and all were successfully treated and remained well and free of lymphoma for over 24 months. Two additional patients were diagnosed at autopsy. We suggest that pulmonary emboli may contribute significantly to the morbidity and mortality of patients undergoing chemotherapy for non-Hodgkin's lymphoma and recommend that patients presenting with respiratory difficulties be evaluated for pulmonary emboli.

AB - Combination chemotherapy has dramatically improved the prognosis of patients with intermediate and high grade histologic subtype of non-Hodgkins' lymphomas. Treatment-related complications, however, are considerable, and a common problem encountered is respiratory distress or respiratory insufficiency. Usually these difficulties have been attributed to infectious etiologies or to chemotherapy-induced interstitial fibrosis, most often involving bleomycin. We describe five patients presenting with respiratory problems several weeks after the initiation of chemotherapy. These patients, who represent 3 percent of all patients treated with a single bleomycin-containing regimen for intermediate or high grade non-Hodgkin's lymphoma, were all initially throught to have chemotherapy-induced interstitial fibrosis but were found on subsequent evaluation to have pulmonary emboli. Of the three patients in whom pulmonary emboli were diagnosed antemortem, two had symptoms suggestive of pulmonary emboli and all were successfully treated and remained well and free of lymphoma for over 24 months. Two additional patients were diagnosed at autopsy. We suggest that pulmonary emboli may contribute significantly to the morbidity and mortality of patients undergoing chemotherapy for non-Hodgkin's lymphoma and recommend that patients presenting with respiratory difficulties be evaluated for pulmonary emboli.

UR - http://www.scopus.com/inward/record.url?scp=0023762317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023762317&partnerID=8YFLogxK

U2 - 10.1378/chest.94.3.589

DO - 10.1378/chest.94.3.589

M3 - Article

VL - 94

SP - 589

EP - 594

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -